Country: United States
Language: English
Source: NLM (National Library of Medicine)
EZETIMIBE (UNII: EOR26LQQ24) (EZETIMIBE - UNII:EOR26LQQ24)
Actavis Pharma, Inc.
EZETIMIBE
EZETIMIBE 10 mg
ORAL
PRESCRIPTION DRUG
Ezetimibe tablets are indicated: - In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). - In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. - In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. - In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). - As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe tablets are used in combinat
Ezetimibe tablets, USP 10 mg, are white to off white, capsule-shaped tablets debossed with "713 " on one side and plain on the other side. They are supplied as follows: NDC 0591-3713-30 bottles of 30 NDC 0591-3713-19 bottles of 90 NDC 0591-3713-05 bottles of 500 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.
Abbreviated New Drug Application
EZETIMIBE- EZETIMIBE TABLET ACTAVIS PHARMA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE EZETIMIBE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR EZETIMIBE TABLETS. EZETIMIBE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2002 RECENT MAJOR CHANGES Indications and Usage (1) 7/2023 Dosage and Administration (2) 7/2023 Contraindications (4) 7/2023 Warnings and Precautions (5.1, 5.2, 5.3) 7/2023 INDICATIONS AND USAGE Ezetimibe is indicated (1): In combination with a statin, or alone when additional low density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. In combination with fenofibrate as an adjunct to diet to reduce elevated LDL C in adults with mixed hyperlipidemia. In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use (1). DOSAGE AND ADMINISTRATION 10-mg orally once daily, with or without food (2) Administer ezetimibe tablets either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant. (2) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets. (2) DOSAGE FORMS AND STRENGTHS Tablets: 10 mg (3) CONTRAINDICATIONS Hyper Read the complete document